"The successful bidding for the negotiation of drugs for 15 rare diseases has made up for the gap in the protection of related diseases. This morning, at the press conference on the "2023 National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue Adjustment" held by the National Medical Security Administration, Huang Xinyu, director of the Pharmaceutical Service Management Department of the National Health Insurance Administration, said in the introduction of the characteristics of the catalogue adjustment that after this batch of rare disease drugs is included in the catalogue, it is expected to benefit nearly 10,000 patients and nearly 10,000 families will rekindle their hope for life.
According to reports, in response to the pain point of "unaffordable drugs" for patients with rare diseases, the National Health Insurance Administration has insisted on taking multiple measures at the same time, canceling the restriction on the approval period of rare disease drugs for three consecutive years in terms of access conditions, and clearly tilting them in the review, calculation and other links, and supporting the priority of eligible rare disease drugs to be included in the medical insurance.
In this adjustment, 15 drugs for rare diseases outside the catalogue were successfully negotiated or bidd, covering 16 rare diseases, filling the gap in drug protection for 10 diseases. In particular, Gaucher disease, myasthenia gravis and other diseases that have not been solved for many years and have a large social impact are included in the catalog, which will produce good social effects.